Literature DB >> 33467121

Soluble ST2 as a Biomarker for Early Complications in Patients with Chronic Thromboembolic Pulmonary Hypertension Treated with Balloon Pulmonary Angioplasty.

Marta Banaszkiewicz1, Arkadiusz Pietrasik2, Michał Florczyk1, Piotr Kędzierski1, Michał Piłka1, Rafał Mańczak1, Janusz Kochman2, Grzegorz Opolski2, Adam Torbicki1, Marcin Kurzyna1, Szymon Darocha1.   

Abstract

BACKGROUND: The aim of the study was to assess soluble ST2 (sST2) concentration and its dynamic changes in the periprocedural period in patients with chronic thromboembolic pulmonary hypertension (CTEPH) treated with balloon pulmonary angioplasty (BPA).
METHODS: We prospectively analyzed 57 procedures of BPA performed in 37 patients with CTEPH. Biomarkers, such as N-terminal pro B-type natriuretic peptide (NT-proBNP), troponin T (TnT), and sST2 were assessed at four time points: Before the BPA procedure, 24 h and 48 h after the procedure, and at the discharge from hospital. Each postprocedural period was assessed for complications.
RESULTS: Before the BPA procedure, median sST2 concentration was 26.56 ng/mL (IQR: 16.66-40.83 ng/mL). sST2 concentration was significantly higher 24 h and 48 h after the BPA compared to the baseline measurements (33.31 ng/mL (IQR: 20.81-62.56), p = 0.000 and 27.45 ng/mL (IQR: 17.66-54.45), p = 0.028, respectively). sST2 level 24 h after the BPA procedure was significantly higher in the group with complications compared to the group without complications in the postprocedural period (97.66 ng/mL (IQR: 53.07-126.18) vs. 26.86 ng/mL (IQR: 19.10-40.12), p = 0.000).
CONCLUSIONS: sST2 concentration in patients with CTEPH treated with BPA changes significantly in the postprocedural period and is significantly higher in the group with complications in postprocedural period.

Entities:  

Keywords:  balloon pulmonary angioplasty; chronic thromboembolic pulmonary hypertension; soluble ST2

Year:  2021        PMID: 33467121      PMCID: PMC7830401          DOI: 10.3390/diagnostics11010133

Source DB:  PubMed          Journal:  Diagnostics (Basel)        ISSN: 2075-4418


  43 in total

1.  Improvement in Quality of Life and Hemodynamics in Chronic Thromboembolic Pulmonary Hypertension Treated With Balloon Pulmonary Angioplasty.

Authors:  Szymon Darocha; Radosław Pietura; Arkadiusz Pietrasik; Justyna Norwa; Anna Dobosiewicz; Michał Piłka; Michał Florczyk; Andrzej Biederman; Adam Torbicki; Marcin Kurzyna
Journal:  Circ J       Date:  2017-02-01       Impact factor: 2.993

2.  Serum soluble ST2 and interleukin-33 levels in patients with pulmonary arterial hypertension.

Authors:  Guido Carlomagno; Giancarlo Messalli; Rosa Marina Melillo; Anna Agnese Stanziola; Carla Visciano; Valentina Mercurio; Massimo Imbriaco; Stefano Ghio; Matteo Sofia; Domenico Bonaduce; Serafino Fazio
Journal:  Int J Cardiol       Date:  2013-01-03       Impact factor: 4.164

3.  Vascular and right ventricular remodelling in chronic thromboembolic pulmonary hypertension.

Authors:  Marion Delcroix; Anton Vonk Noordegraaf; Elie Fadel; Irene Lang; Gérald Simonneau; Robert Naeije
Journal:  Eur Respir J       Date:  2012-08-16       Impact factor: 16.671

Review 4.  Emerging role of interleukin-33 in autoimmune diseases.

Authors:  Cheng Pei; Mark Barbour; Karen J Fairlie-Clarke; Debbie Allan; Rong Mu; Hui-Rong Jiang
Journal:  Immunology       Date:  2014-01       Impact factor: 7.397

5.  Prognostic value of right ventricular longitudinal peak systolic strain in patients with pulmonary hypertension.

Authors:  Marlieke L A Haeck; Roderick W C Scherptong; Nina Ajmone Marsan; Eduard R Holman; Martin J Schalij; Jeroen J Bax; Hubert W Vliegen; Victoria Delgado
Journal:  Circ Cardiovasc Imaging       Date:  2012-08-08       Impact factor: 7.792

6.  Vascular Injury Is a Major Cause of Lung Injury After Balloon Pulmonary Angioplasty in Patients With Chronic Thromboembolic Pulmonary Hypertension.

Authors:  Kentaro Ejiri; Aiko Ogawa; Shinya Fujii; Hiroshi Ito; Hiromi Matsubara
Journal:  Circ Cardiovasc Interv       Date:  2018-12       Impact factor: 6.546

Review 7.  The pathophysiology of chronic thromboembolic pulmonary hypertension.

Authors:  Gérald Simonneau; Adam Torbicki; Peter Dorfmüller; Nick Kim
Journal:  Eur Respir Rev       Date:  2017-03-29

8.  Serial monitoring of soluble interleukin family member ST2 in patients with acutely decompensated heart failure.

Authors:  S Manzano-Fernández; J L Januzzi; F J Pastor-Pérez; J C Bonaque-González; M Boronat-Garcia; D A Pascual-Figal; S Montalban-Larrea; M Navarro-Peñalver; J M Andreu-Cayuelas; M Valdés
Journal:  Cardiology       Date:  2012-07-24       Impact factor: 1.869

9.  Pulmonary edema predictive scoring index (PEPSI), a new index to predict risk of reperfusion pulmonary edema and improvement of hemodynamics in percutaneous transluminal pulmonary angioplasty.

Authors:  Takumi Inami; Masaharu Kataoka; Nobuhiko Shimura; Haruhisa Ishiguro; Ryoji Yanagisawa; Hiroki Taguchi; Keiichi Fukuda; Hideaki Yoshino; Toru Satoh
Journal:  JACC Cardiovasc Interv       Date:  2013-06-14       Impact factor: 11.195

10.  pROC: an open-source package for R and S+ to analyze and compare ROC curves.

Authors:  Xavier Robin; Natacha Turck; Alexandre Hainard; Natalia Tiberti; Frédérique Lisacek; Jean-Charles Sanchez; Markus Müller
Journal:  BMC Bioinformatics       Date:  2011-03-17       Impact factor: 3.307

View more
  4 in total

Review 1.  Pulmonary hypertension in developing countries: Limiting factors in time to diagnosis, specialised medications and contextualised recommendations.

Authors:  G J Maarman
Journal:  Afr J Thorac Crit Care Med       Date:  2022-05-05

2.  Right Ventricle Remodeling in Chronic Thromboembolic Pulmonary Hypertension.

Authors:  Jixiang Liu; Peiran Yang; Han Tian; Kaiyuan Zhen; Colm McCabe; Lan Zhao; Zhenguo Zhai
Journal:  J Transl Int Med       Date:  2022-07-02

Review 3.  Circulating Blood-Based Biomarkers in Pulmonary Hypertension.

Authors:  Marta Banaszkiewicz; Aleksandra Gąsecka; Szymon Darocha; Michał Florczyk; Arkadiusz Pietrasik; Piotr Kędzierski; Michał Piłka; Adam Torbicki; Marcin Kurzyna
Journal:  J Clin Med       Date:  2022-01-13       Impact factor: 4.241

4.  Soluble ST2 as a Potential Biomarker for Risk Assessment of Pulmonary Hypertension in Patients Undergoing TAVR?

Authors:  Elke Boxhammer; Moritz Mirna; Laura Bäz; Nina Bacher; Albert Topf; Brigitte Sipos; Marcus Franz; Daniel Kretzschmar; Uta C Hoppe; Alexander Lauten; Michael Lichtenauer
Journal:  Life (Basel)       Date:  2022-03-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.